Intellia Therapeutics Inc at JPMorgan Healthcare Conference (Virtual) Transcript
Good afternoon, everyone, and thank you for joining us today. My name is Michael Peters, and I'm an analyst in JPMorgan's Healthcare Investment Banking Group.
In this session, we're delighted to introduce Intellia Therapeutics, a leading stage genome editing company, leveraging CRISPR-based technologies. If you have any questions throughout the presentation, please submit them by clicking the blue button at the bottom of your screen, and we'll address them at the end of the prepared remarks.
With that, I'm pleased to introduce you to John Leonard, CEO of Intellia.
Thank you. Good afternoon. I'm John Leonard, President and CEO of Intellia Therapeutics, and I'm pleased to be starting off the year presenting at the JPMorgan 40th Annual Healthcare Conference.
As we enter 2022, it's apparent that genome editing holds the power to revolutionize medicine by treating disease in ways that were inconceivable prior to the Nobel Prize-winning discovery of
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
